Clinical Trials Conditions Download Patients 
TheAnswerPage
JANUARY 11, 2022
Are you able to answer your patients’ medical marijuana questions? We also provide free downloadable resources: ‘The Endocannabinoid System and Medical Marijuana in 15 minutes!’ and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ Unfortunately, this did not occur.
Cannabis Law Report
JUNE 30, 2021
Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
MARCH 8, 2020
In January of 2020, the Journal of the American College of Cardiology published a review titled Marijuana Use in Patients With Cardiovascular Disease. Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. population, has an arrhythmia.
Greencamp
FEBRUARY 17, 2019
Usually, the diagnosis involves excluding conditions like parasitic infections, lactose intolerance tests and small intestinal bacterial overgrowth which all produce symptoms like IBS. Constant gut symptoms often lead to the development of other conditions like anxiety , depression , migraines , sleeping problems and fatigue.
CannaMD
MARCH 8, 2021
If you’re a Florida medical marijuana patient, chances are you’ve heard of House Bill 1455 – a proposed bill making its rounds through the state legislature as we speak. But, behind the outrage, lies a larger conversation regarding free speech, fair pricing, and the sanctity of the physician-patient relationship.
Cannabis Law Report
JULY 15, 2022
“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.
Project CBD
FEBRUARY 28, 2023
Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: www.fda.gov/media/131878/download. US Food and Drug Administration website. Accessed October 17, 2022.
Expert insights. Personalized for you.
98 
Let's personalize your content